Literature DB >> 25485535

Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.

Ya'an Kang1, Ran Zhang1, Rei Suzuki2, Shao-qiang Li3, David Roife1, Mark J Truty4, Deyali Chatterjee5, Ryan M Thomas6, James Cardwell7, Yu Wang8, Huamin Wang9, Matthew H Katz1, Jason B Fleming1.   

Abstract

Many commercially available cell lines have been in culture for ages, acquiring phenotypes that differ from the original cancers from which these cell lines were derived. Therefore, research on new cell lines could improve the success rates of translational research in cancer. We have developed methods for the isolation and culture of human pancreatic ductal adenocarcinoma (PDAC) cells from murine xenografts of human PDAC. We hypothesize that phenotypes of PDAC cells are modified by in vitro culture conditions over time and by in vivo implantation. Patient-derived xenografts were created in immunodeficient mice using surgically resected tumor specimens. These murine xenografts were then used to establish human PDAC cell lines in culture. Earlier (<5) passage and later (>20) passage cell lines were evaluated separately regarding proliferation, cell cycle, genetic mutations, invasiveness, chemosensitivity, tumorigenesis, epithelial-mesenchymal transition (EMT) status, and proteomics. Later passage cells accelerated their doubling time and colony formation, and were more concentrated in the G0/G1 phase and less in the G2/M checkpoint phase. Later passage cells were more sensitive to gemcitabine and 5-fluorouracil than earlier passage cells, but all four new cell lines were more chemo-resistant compared with commercial ATCC cell lines. EMT induction was observed when establishing and passaging cell lines in vitro and furthermore by growing them as subcutaneous tumors in vivo. This study demonstrates a novel approach to the establishment of PDAC cell lines and observes a process by which newly established cell lines undergo phenotypic changes during in vitro culture and in vivo tumorigenesis. This may help explain differences of treatment effects often observed between experiments conducted in vitro, in vivo, and in human clinical trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25485535      PMCID: PMC4670045          DOI: 10.1038/labinvest.2014.143

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

1.  Intracellular substrates of brain-enriched receptor protein tyrosine phosphatase rho (RPTPrho/PTPRT).

Authors:  Julie A Besco; Rob Hooft van Huijsduijnen; Adrienne Frostholm; Andrej Rotter
Journal:  Brain Res       Date:  2006-09-14       Impact factor: 3.252

2.  Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.

Authors:  Ying Liu; Walter F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

3.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.

Authors:  Zhihu Ding; Chang-Jiun Wu; Gerald C Chu; Yonghong Xiao; Dennis Ho; Jingfang Zhang; Samuel R Perry; Emma S Labrot; Xiaoqiu Wu; Rosina Lis; Yujin Hoshida; David Hiller; Baoli Hu; Shan Jiang; Hongwu Zheng; Alexander H Stegh; Kenneth L Scott; Sabina Signoretti; Nabeel Bardeesy; Y Alan Wang; David E Hill; Todd R Golub; Meir J Stampfer; Wing H Wong; Massimo Loda; Lorelei Mucci; Lynda Chin; Ronald A DePinho
Journal:  Nature       Date:  2011-02-02       Impact factor: 49.962

4.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.

Authors:  Michael P Kim; Douglas B Evans; Huamin Wang; James L Abbruzzese; Jason B Fleming; Gary E Gallick
Journal:  Nat Protoc       Date:  2009-10-29       Impact factor: 13.491

Review 5.  Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

Authors:  Katherine M Sheehan; Valerie S Calvert; Elaine W Kay; Yiling Lu; David Fishman; Virginia Espina; Joy Aquino; Runa Speer; Robyn Araujo; Gordon B Mills; Lance A Liotta; Emanuel F Petricoin; Julia D Wulfkuhle
Journal:  Mol Cell Proteomics       Date:  2005-01-25       Impact factor: 5.911

Review 6.  Phenotype and genotype of pancreatic cancer cell lines.

Authors:  Emily L Deer; Jessica González-Hernández; Jill D Coursen; Jill E Shea; Josephat Ngatia; Courtney L Scaife; Matthew A Firpo; Sean J Mulvihill
Journal:  Pancreas       Date:  2010-05       Impact factor: 3.327

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

8.  In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status.

Authors:  Cristina A Metildi; Sharmeela Kaushal; Robert M Hoffman; Michael Bouvet
Journal:  J Surg Res       Date:  2013-04-05       Impact factor: 2.192

9.  Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells.

Authors:  Zhe Chang; Zhongkui Li; Xiaoyang Wang; Ya'an Kang; Yuhui Yuan; Jiangong Niu; Huamin Wang; Deyali Chatterjee; Jason B Fleming; Min Li; James L Abbruzzese; Paul J Chiao
Journal:  Clin Cancer Res       Date:  2013-01-22       Impact factor: 12.531

10.  Assignment1 of the E-cadherin gene (CDH1) to chromosome 16q22.1 by radiation hybrid mapping.

Authors:  D G Huntsman; C Caldas
Journal:  Cytogenet Cell Genet       Date:  1998
View more
  27 in total

1.  Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.

Authors:  David Roife; Ya'an Kang; Li Wang; Bingliang Fang; Stephen G Swisher; Jeffrey E Gershenwald; Shanna Pretzsch; Colin P Dinney; Matthew H G Katz; Jason B Fleming
Journal:  Surgery       Date:  2017-01-09       Impact factor: 3.982

2.  Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.

Authors:  Aslamuzzaman Kazi; Shengyan Xiang; Hua Yang; Liwei Chen; Perry Kennedy; Muhammad Ayaz; Steven Fletcher; Christopher Cummings; Harshani R Lawrence; Francisca Beato; Ya'an Kang; Michael P Kim; Andrea Delitto; Patrick W Underwood; Jason B Fleming; Jose G Trevino; Andrew D Hamilton; Said M Sebti
Journal:  Clin Cancer Res       Date:  2019-06-21       Impact factor: 12.531

3.  Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.

Authors:  Kien Pham; Daniel Delitto; Andrea E Knowlton; Emily R Hartlage; Ricky Madhavan; David H Gonzalo; Ryan M Thomas; Kevin E Behrns; Thomas J George; Steven J Hughes; Shannon M Wallet; Chen Liu; Jose G Trevino
Journal:  Am J Pathol       Date:  2016-04-18       Impact factor: 4.307

4.  Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.

Authors:  Bingbing Dai; David Roife; Ya'an Kang; Joy Gumin; Mayrim V Rios Perez; Xinqun Li; Michael Pratt; Rolf A Brekken; Juan Fueyo-Margareto; Frederick F Lang; Jason B Fleming
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

5.  Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection.

Authors:  Christina L Roland; Lee F Starker; Y Kang; Deyali Chatterjee; Jeannelyn Estrella; Asif Rashid; Matthew H Katz; Thomas A Aloia; Jeffrey E Lee; Arvind Dasari; James C Yao; Jason B Fleming
Journal:  Surgery       Date:  2016-11-03       Impact factor: 3.982

6.  Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation.

Authors:  Yan Wang; Jung-Mao Hsu; Ya'an Kang; Yongkun Wei; Pei-Chih Lee; Shing-Jyh Chang; Yi-Hsin Hsu; Jennifer L Hsu; Hung-Ling Wang; Wei-Chao Chang; Chia-Wei Li; Hsin-Wei Liao; Shih-Shin Chang; Weiya Xia; How-Wen Ko; Chao-Kai Chou; Jason B Fleming; Huamin Wang; Rosa F Hwang; Yue Chen; Jun Qin; Mien-Chie Hung
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

7.  IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma.

Authors:  Song Gao; Yan Sun; Xuebin Zhang; Limei Hu; Yuexin Liu; Corrine Yingxuan Chua; Lynette M Phillips; He Ren; Jason B Fleming; Huamin Wang; Paul J Chiao; Jihui Hao; Wei Zhang
Journal:  Cancer Res       Date:  2016-09-22       Impact factor: 12.701

8.  Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors.

Authors:  Ya'an Kang; David Roife; Yeonju Lee; Hailong Lv; Rei Suzuki; Jianhua Ling; Mayrim V Rios Perez; Xinqun Li; BingBing Dai; Michael Pratt; Mark J Truty; Deyali Chatterjee; Huamin Wang; Ryan M Thomas; Yu Wang; Eugene J Koay; Paul J Chiao; Matthew H Katz; Jason B Fleming
Journal:  Clin Cancer Res       Date:  2016-04-28       Impact factor: 12.531

9.  A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.

Authors:  Eugene J Koay; Yeonju Lee; Vittorio Cristini; John S Lowengrub; Ya'an Kang; F Anthony San Lucas; Brian P Hobbs; Rong Ye; Dalia Elganainy; Muayad Almahariq; Ahmed M Amer; Deyali Chatterjee; Huaming Yan; Peter C Park; Mayrim V Rios Perez; Dali Li; Naveen Garg; Kim A Reiss; Shun Yu; Anil Chauhan; Mohamed Zaid; Newsha Nikzad; Robert A Wolff; Milind Javle; Gauri R Varadhachary; Rachna T Shroff; Prajnan Das; Jeffrey E Lee; Mauro Ferrari; Anirban Maitra; Cullen M Taniguchi; Michael P Kim; Christopher H Crane; Matthew H Katz; Huamin Wang; Priya Bhosale; Eric P Tamm; Jason B Fleming
Journal:  Clin Cancer Res       Date:  2018-08-06       Impact factor: 12.531

10.  Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer.

Authors:  Ying-Nai Wang; Heng-Huan Lee; Chao-Kai Chou; Wen-Hao Yang; Yongkun Wei; Chun-Te Chen; Jun Yao; Jennifer L Hsu; Cihui Zhu; Haoqiang Ying; Yuanqing Ye; Wei-Jan Wang; Seung-Oe Lim; Weiya Xia; How-Wen Ko; Xiuping Liu; Chang-Gong Liu; Xifeng Wu; Huamin Wang; Donghui Li; Laura R Prakash; Matthew H Katz; Yaan Kang; Michael Kim; Jason B Fleming; David Fogelman; Milind Javle; Anirban Maitra; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2018-03-29       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.